Beximco Pharmaceuticals Plc.
(LSE) BXP
Beximco Pharmaceuticals Plc. Financials at a Glance
Market Cap
£218.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
BDT 51.41B
Net Income (TTM)
BDT 8.05B
EPS (TTM)
£0.00
P/E Ratio
4.93
Dividend
£0.00
Beta (Volatility)
0.03 (Low)
Dividend
£0.00
Beta (Volatility)
0.03 (Low)
Price
£0.48
Volume
95,932
Open
£0.49
Price
£0.48
Volume
95,932
Open
£0.49
Previous Close
£0.48
Daily Range
£0.48 - £0.48
52-Week Range
£0.37 - £0.55
Estimated Earnings Date
May 21, 2026
Dividend
£0.00
Beta (Volatility)
0.03 (Low)
Price
£0.48
Volume
95,932
Open
£0.49
Previous Close
£0.48
Daily Range
£0.48 - £0.48
52-Week Range
£0.37 - £0.55
Estimated Earnings Date
May 21, 2026
BXP News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Beximco Pharmaceuticals Plc.
Industry
Pharmaceuticals
Sector
Health CareEmployees
1,223
CEO
Iqbal Ahmed
Website
www.beximcopharma.comHeadquarters
Dhaka, DA 1205, BD
BXP Financials
Key Financial Metrics (TTM)
Gross Margin
46.40%
Operating Margin
21.61%
Net Income Margin
16.57%
Return on Equity
7.76%
Return on Capital
16.07%
Return on Assets
5.86%
Earnings Yield
20.28%
Dividend Yield
0.00%
Payout Ratio
0.62%
Stock Overview
Market Cap
£218.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
446.11M
Volume
95.93K
Avg. Volume
55.78K
Financials (TTM)
Gross Profit
BDT 23.69B
Operating Income
BDT 11.01B
EBITDA
BDT 11.99B
Operating Cash Flow
BDT 6.91B
Capital Expenditure
-BDT 2.44B
Free Cash Flow
BDT 4.47B
Cash & ST Invst.
BDT 5.15B
Total Debt
BDT 3.11B
Beximco Pharmaceuticals Plc. Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
BDT 13.20B
+16.4%
Gross Profit
BDT 5.83B
+15.8%
Gross Margin
44.17%
N/A
Market Cap
£218.59MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
£36.43K
N/A
Employees
6,000
N/A
Net Income
BDT 2.15B
+45.4%
EBITDA
BDT 3.28B
+45.1%
Quarterly Fundamentals
Total Cash
BDT 5.15B
+388.5%
Total Debt
BDT 3.11B
-36.4%
Accounts Receivable
BDT 3.78B
-41.5%
Inventory
BDT 15.31B
+17.6%
Long Term Debt
BDT 1.28B
-27.3%
Short Term Debt
BDT 1.84B
-41.5%
Return on Assets
5.86%
N/A
Return on Invested Capital
8.36%
N/A
Free Cash Flow
BDT 2.22B
+29.6%
Operating Cash Flow
BDT 2.41B
+13.1%